WallStSmart

Alpha Tau Medical Ltd (DRTS)vsRegeneron Pharmaceuticals Inc (REGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

REGN leads profitability with a 27.9% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 66/100 (B-).

DRTS

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: -1.47

REGN

Strong Buy

66

out of 100

Grade: B-

Growth: 5.3Profit: 8.0Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 4.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DRTS.

REGNUndervalued (+44.4%)

Margin of Safety

+44.4%

Fair Value

$1404.34

Current Price

$781.49

$622.85 discount

UndervaluedFair: $1404.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DRTS0 strengths · Avg: 0/10

No standout strengths identified

REGN6 strengths · Avg: 9.3/10
Operating MarginProfitability
33.1%10/10

Strong operational efficiency at 33.1%

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4410/10

Safe zone — low bankruptcy risk

Market CapQuality
$80.46B9/10

Large-cap with strong market position

Profit MarginProfitability
27.9%9/10

Keeps 28 of every $100 in revenue as profit

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

DRTS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.33B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

REGN2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-4.5%2/10

Earnings declined 4.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : DRTS

DRTS has a balanced fundamental profile.

Bull Case : REGN

The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : DRTS

The primary concerns for DRTS are Revenue Growth, EPS Growth, Market Cap.

Bear Case : REGN

The primary concerns for REGN are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

DRTS profiles as a value stock while REGN is a growth play — different risk/reward profiles.

DRTS carries more volatility with a beta of 1.21 — expect wider price swings.

REGN is growing revenue faster at 16.7% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

REGN scores higher overall (66/100 vs 17/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alpha Tau Medical Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.

Visit Website →

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Want to dig deeper into these stocks?